15 results about "Spliceosome" patented technology

Disclosed herein include methods, compositions, and kits suitable for use in treating a hematological cancer in a subject. In some embodiments, the method comprises determining the presence or absence of at least one mutation in one or more genes encoding a spliceosome protein in sample nucleic acids from the subject; and administering onvansertib and decitabine to the subject, if the at least one mutation in one or more genes encoding a spliceosome protein is determined to be present in the sample nucleic acids, thereby reducing or inhibiting progression of the hematological cancer in the subject.

The invention discloses a Jiangxi No. 1 CcMYB18 gene as well as a variable spliceosome and application thereof, and belongs to the technical field of plant molecular biology. The invention provides a Jiangxi No. 1 CcMYB18 gene, the nucleotide sequence of the Jiangxi No. 1 CcMYB18 gene is shown as SEQ ID NO.1 in a sequence table, and the amino acid sequence of the Jiangxi No. 1 CcMYB18 gene is shown as SEQ ID NO.3 in the sequence table. The nucleotide sequence of the variable spliceosome is as shown in SEQ ID NO.1 in a sequence table, and the amino acid sequence of the variable spliceosome is as shown in SEQ ID NO.3 in the sequence table. The CcMYB18 gene and a variable spliceosome transgenic positive strain thereof are obtained through an arabidopsis thaliana flower immersion method. Compared with WT, the whole CcMYB18 transgenic plant shows the expression that rosette leaves and stalks are obviously purple, it is determined that CcMYB18 can promote accumulation of anthocyanin, and a variable spliceosome of CcMYB18 is opposite, and an effective molecular tool is provided for improving the ornamental value of plants through genetic engineering.

A synthetic nucleic acid expression system for production of a transcript of interest in a predefined cell-state is provided, the system comprising (a) a first nucleic acid sequence comprising a first promoter operably linked to a nucleic acid sequence encoding a first trans-spliceable pre-mRNA sequence comprising at least one exon encoding a 5′ fragment of said transcript of interest and a first RNA sequence required for spliceosome-dependent trans-splicing; and (b) a second nucleic acid sequence comprising a second promoter operably linked to a nucleic acid sequence encoding a second trans-spliceable pre-mRNA sequence comprising at least one exon encoding a 3′ fragment of said transcript of interest and a second RNA sequence required for spliceosome-dependent trans-splicing; wherein said first promoter and said second promoter are different and each one is specifically regulated by said predefined cell-state.

Disclosed are methods and compositions for promoting trans-splicing. In some embodiments, the composition comprises an engineered small nuclear RNA that promotes trans-splicing of a target RNA molecule. The composition may further comprise an RNA donor molecule.

The present invention provides tumor-specific neoantigenic peptides resulting from mutations in spliceosome factor 3b subunit 1 (SF3B1), vaccinal compositions comprising such tumor-specific neoantigenic peptides, nucleic acids, antibodies or fragments thereof and immune cells that can be used in cancer therapy or prevention.

The present application relates to a primer combination for lung cancer detection and its application in lung cancer diagnosis, in particular, a technology for specifically detecting CIZ1b splice body RNA through real-time fluorescent quantitative PCR technology. The method combines blocker sequence to inhibit non-specific amplification of CIZ1a splice body by designing specific primers and probes, and ensures high-specificity detection of CIZ1b splice body RNA. The detection samples include lung cancer tissues and plasma, and cDNA is generated through reverse transcription after RNA extraction of the samples, and real-time fluorescent quantitative analysis is performed. Meanwhile, the method introduces an internal reference gene B2M for standardization correction, and improves the sensitivity and accuracy of the detection. The present application provides a non-invasive and reliable early lung cancer diagnosis tool, which has good clinical application potential.

The present invention provides tumor-specific neoantigenic peptides resulting from mutations in spliceosome factor 3b subunit 1 (SF3B1), vaccinal compositions comprising such tumor-specific neoantigenic peptides, nucleic acids, antibodies or fragments thereof and immune cells that can be used in cancer therapy or prevention.

The invention discloses an expression method of amylase in pichia pastoris, and belongs to the field of gene engineering. The method is characterized in that pGAPZ alpha A is used as a carrier, a translation-related functional gene is inserted between a GAP promoter and an AOX1 terminator to construct a recombinant plasmid, and the translation-related functional gene is selected from a coding protein kinase gene, a coding cytoplasm RNA binding protein gene or a coding spliceosome protein gene; and after linearization, electrotransduction is carried out to introduce into pichia pastoris containing barley alpha-amylase genes, and fermentation is induced through screening. According to the method, related functional genes are translated through co-expression, the secretory expression of amylase is remarkably improved, the enzyme activity is improved by 106.9% at most, and industrial production requirements are met.

The invention provides a construction method of an expression vector of eukaryotic genes in prokaryotes, and belongs to the field of molecular biology. The method comprises the following steps: (a) designing a PCR (Polymerase Chain Reaction) primer pair for amplifying each exon in a specific transcription spliceosome cds sequence; (b) respectively amplifying each exon by using the PCR primer pair designed in the step (a) to obtain a PCR fragment of each exon; (c) mixing the n exon fragments obtained in the step (b) as a template, and carrying out overlapping PCR by using the forward primer P1-F of the first exon and the reverse primer Pn-R of the final exon to obtain a complete cds fragment of the specific transcription spliceosome; and (d) purifying and recovering the cds fragment of the specific transcription spliceosome obtained in the step (c), and connecting the cds fragment to a prokaryotic expression vector. Therefore, the problem that the cds fragment of the target transcription spliceosome cannot be obtained due to unknown temporal-spatial expression information of a luxury gene or a specific transcript is solved.

This disclosure provides an engineered polynucleotide that interacts with a pre-mRNA and a spliceosome to regulate gene expression. The engineered polynucleotide may have stem-loop structure that recruits the spliceosome and targeting sequences that are complementary to a target sequence at an exon-intron splice junction and may include nucleotides with 2′ modifications and phosphorothioate linkages. The engineered polynucleotide can be administered to a subject to treat a cancer.

This invention discloses the application of the OsCAX1a gene in the breeding of cold-adapted rice varieties, belonging to the field of plant genetic engineering. The amino acid sequences of the two different spliceosome translation proteins encoded by the OsCAX1a gene are shown in SEQ ID NO.1 and SEQ ID NO.2, respectively, and the CDS sequences are shown in SEQ ID NO.3 and SEQ ID NO.4, respectively. This invention reveals that OsCAX1a is a negative regulator of rice cold stress adaptation. Knocking out the OsCAX1a gene inhibits rice growth and development in the early stages, but as the heading stage lengthens and the plant enters the low-temperature growth period, the mutant exhibits significantly better cold adaptation, ultimately manifested in an increased number of tillers and increased grain yield per plant. By selecting varieties with low expression levels of this gene or by mutating the gene through gene editing, superior cold-adapted rice varieties tolerant to low-temperature stress can be cultivated, showing promising application prospects.

The present disclosure provides novel pladienolide compounds according to Formula I:pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancer, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are methods of treating cancers by administering at least one compound disclosed herein and at least one additional therapy.

Provided is a method for preparing a circular RNA or chimeric RNA by means of an RNA self-splicing ribozyme or self-splicing pair. By means of a self-splicing reaction, both ends of two independent linear RNA molecules are respectively linked to each other to form a circular RNA molecule; or one end of one linear RNA molecule is linked to one end of the other independent RNA molecule to form a chimeric RNA molecule. The chemical modification levels of the two linear RNA molecules may be independently regulated, and then the two linear RNA molecules are linked to form a circular RNA or a chimeric RNA molecule, thereby achieving chemical modification with controllable modification types and modification levels for specific regions of the circular RNA molecule or the chimeric RNA molecule. The site-specific controllable RNA modification method can significantly improve the likelihood of RNAs becoming therapeutics and reduce toxic and side effects, thereby promoting the development of RNA vaccines and drugs.

This disclosure concerns an engineered polynucleotide that interacts with a pre-mRNA and a spliceosome to regulate gene expression. The engineered polynucleotide may have stem-loop structure that recruits the spliceosome and targeting sequences that are complementary to a target sequence at an exon-intron splice junction and may include nucleotides with 2′ modifications and phosphorothioate linkages. The engineered polynucleotide can be administered to a subject to treat a neurodegenerative disease.